Kojin Bio hits limit down in afternoon session on forecast of 60% drop in operating profit for FY March 2027

Fri May 15, 2026 3:13 pm JST Catalyst

Kojin Bio <177A> plunged to its daily limit-down in the afternoon session, falling 400 yen from the previous trading day to 1,278 yen. Around 2:30 p.m. today, the company announced its results for the fiscal year ended March 2026 and disclosed its earnings forecast for the fiscal year ending March 2027. Kojin Bio projects sales of 4.722 billion yen, down 4.4% year-on-year, and operating profit of 137 million yen, down 59.8%, triggering heavy selling on the significant profit decline. The forecast anticipates a drop in demand for infection-related products, such as antigen test kits, in the microbiology business.

For the fiscal year ended March 2026, sales totaled 4.939 billion yen, down 5.1% year-on-year, and operating profit came to 341 million yen, down 65.5%. The microbiology business struggled due to a reactionary decline following strong growth in COVID-19 and influenza-related products in the previous year. The cell processing business also saw significant revenue and profit declines as the number of inbound patients decreased amid deteriorating Japan-China relations.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Kojin Bio hits limit down in afternoon session on forecast of 60% drop in operating profit for FY March 2027

Related Articles